We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+3.02%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$751M
AUM Growth
-$32.5M
Cap. Flow
+$2.11M
Cap. Flow %
0.28%
Top 10 Hldgs %
35.59%
Holding
104
New
11
Increased
46
Reduced
31
Closed
15

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$22.1M
2
SYK icon
Stryker
SYK
+$18.4M
3
VRDN icon
Viridian Therapeutics
VRDN
+$14.4M
4
MCK icon
McKesson
MCK
+$12.9M
5
UNH icon
UnitedHealth
UNH
+$11.4M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$23.8M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$16.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$12.7M
4
LLY icon
Eli Lilly
LLY
+$10.1M
5
UTHR icon
United Therapeutics
UTHR
+$9.76M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
76
DELISTED
Nuvalent
NUVL
$1.85M 0.25%
23,588
+188
+0.8% +$17.6K
IRWD icon
77
Ironwood Pharmaceuticals
IRWD
$714M
$1.81M 0.24%
408,535
-46,942
-10% -$190K
ANNX icon
78
Annexon
ANNX
$873M
$1.7M 0.23%
330,849
+2,236
+0.7% +$13.8K
OSCR icon
79
Oscar Health
OSCR
$9.14B
$1.68M 0.22%
125,000
-125,000
-50% -$2.01M
BCRX icon
80
BioCryst Pharmaceuticals
BCRX
$2.71B
$1.63M 0.22%
216,881
-247,167
-53% -$1.88M
LUNG icon
81
Pulmonx
LUNG
$98.4M
$1.41M 0.19%
207,853
+1,409
+0.7% +$9.28K
RVPH
82
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$931K 0.12%
25,714
+104
+0.4% +$2.9K
ARDX icon
83
Ardelyx
ARDX
$1.03B
$901K 0.12%
177,794
+50,854
+40% +$281K
THRD
84
DELISTED
Third Harmonic Bio
THRD
$892K 0.12%
86,707
-151,113
-64% -$1.88M
ENTX icon
85
Entera Bio
ENTX
$138M
$877K 0.12%
413,732
+2,656
+0.6% +$4.96K
CBLL
86
CeriBell Inc
CBLL
$879M
$828K 0.11%
+32,002
New +$872K
CLYM
87
Climb Bio
CLYM
$827M
$523K 0.07%
290,491
+11,716
+4% +$42.4K
YARW
88
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$512K 0.07%
3,059
-1,000
-25% -$131K
FOCL
89
EDAP TMS S.A.
FOCL
$178M
$342K 0.05%
154,832
– –
AGIO icon
90
Agios Pharmaceuticals
AGIO
$2.04B
– –
-285,099
Closed -$12.7M
AKYA
91
DELISTED
Akoya BioSciences
AKYA
– –
-376,131
Closed -$1.02M
ANAB icon
92
AnaptysBio
ANAB
$1.69B
– –
-138,100
Closed -$4.63M
APLT
93
DELISTED
Applied Therapeutics
APLT
– –
-907,294
Closed -$7.71M
AVDL
94
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-254,827
Closed -$3.34M
ELAN icon
95
Elanco Animal Health
ELAN
$11.1B
– –
-127,812
Closed -$1.88M
EPIX
96
DELISTED
ESSA Pharma
EPIX
– –
-345,902
Closed -$2.1M
ESPR
97
DELISTED
Esperion Therapeutics
ESPR
– –
-903,140
Closed -$1.49M
TFX icon
98
Teleflex
TFX
$6.03B
– –
-96,144
Closed -$23.8M
TGTX icon
99
TG Therapeutics
TGTX
$7.58B
– –
-126,471
Closed -$2.96M
TKNO icon
100
Alpha Teknova
TKNO
$397M
– –
-251,026
Closed -$1.21M
1 2 3
4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Parkman Healthcare Partners held 104 positions worth $751M, down 4.2% from $783M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Parkman Healthcare Partners's Q4 2024 filing shows 11 new, 46 increased, 31 reduced and 15 closed positions. Its largest new stake was McKesson: 23,000 shares worth $13.1M. The largest sale was Teleflex, an estimated $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Parkman Healthcare Partners's largest Q4 2024 buy was McKesson: 23,000 shares worth $13.1M.
  • Parkman Healthcare Partners added most to Gilead Sciences in Q4 2024, an estimated $22.1M increase.
  • Parkman Healthcare Partners's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $10.1M.
  • Parkman Healthcare Partners fully exited Teleflex in Q4 2024, selling an estimated $23.8M.
  • Parkman Healthcare Partners's ten largest holdings make up 36% of its $751M portfolio in Q4 2024.
  • Parkman Healthcare Partners opened 11 new positions and closed 15 in Q4 2024.
  • Parkman Healthcare Partners's portfolio value fell 4.2% quarter-over-quarter to $751M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2024, filed 14 Feb 2025.